Ruckle David, Keheila Mohamed, West Benjamin, Baron Pedro, Villicana Rafael, Mattison Braden, Thomas Alex, Thomas Jerry, De Vera Michael, Kore Arputharaj, Wai Philip, Baldwin D Duane
Department of Urology, Loma Linda University Health, Loma Linda, CA, USA.
Department of Transplant and Transplant Nephrology, Loma Linda University Health, Loma Linda, CA, USA.
Clin Kidney J. 2018 Nov 15;12(3):437-442. doi: 10.1093/ckj/sfy107. eCollection 2019 Jun.
The use of marijuana in the USA has been steadily increasing over the last 10 years. This study is the first to investigate the effect of marijuana use by live kidney donors upon outcomes in both donors and recipients.
Living kidney donor transplants performed between January 2000 and May 2016 in a single academic institution were retrospectively reviewed. Donor and recipient groups were each divided into two groups by donor marijuana usage. Outcomes in donor and recipient groups were compared using -test, Chi-square and mixed linear analysis (P < 0.05 considered significant).
This was 294 living renal donor medical records were reviewed including 31 marijuana-using donors (MUD) and 263 non-MUDs (NMUD). It was 230 living kidney recipient records were reviewed including 27 marijuana kidney recipients (MKRs) and 203 non-MKRs (NMKR). There was no difference in donor or recipient perioperative characteristics or postoperative outcomes based upon donor marijuana use (P > 0.05 for all comparisons). There was no difference in renal function between NMUD and MUD groups and no long-term difference in kidney allograft function between NMKR and MKR groups.
Considering individuals with a history of marijuana use for living kidney donation could increase the donor pool and yield acceptable outcomes.
在过去10年中,美国大麻的使用量一直在稳步增加。本研究首次调查了活体肾供者使用大麻对供者和受者结局的影响。
对2000年1月至2016年5月在单一学术机构进行的活体肾供者移植进行回顾性研究。根据供者大麻使用情况,将供者和受者组各分为两组。使用t检验、卡方检验和混合线性分析比较供者和受者组的结局(P<0.05认为具有显著性)。
共回顾了294份活体肾供者的医疗记录,包括31名使用大麻的供者(MUD)和263名未使用大麻的供者(NMUD)。共回顾了230份活体肾受者记录,包括27名接受大麻肾移植的受者(MKR)和203名未接受大麻肾移植的受者(NMKR)。根据供者大麻使用情况,供者或受者的围手术期特征或术后结局没有差异(所有比较的P>0.05)。NMUD组和MUD组的肾功能没有差异,NMKR组和MKR组的肾移植长期功能也没有差异。
考虑有大麻使用史的个体进行活体肾捐赠可能会增加供者库并产生可接受的结局。